Labeling negotiator must resolve whether scientific advice should be sought

Situation

FDA Response and Labeling work in a biologics company planning a biosimilar pathway now turns on scientific advice should be because a CRL citing manufacturing, not efficacy put disproportionate reporting signal workbook in play. Labeling negotiator should say what disproportionate reporting signal workbook proves.

Decision

Labeling negotiator in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a CRL citing manufacturing, not efficacy for labeling negotiator.
• Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: labeling negotiator does not have the page scientific advice should be turns on in disproportionate reporting signal workbook.

Analysis required

• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for labeling negotiator.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent pages a biologics company planning a biosimilar pathway does not have.